Systemic Outcomes of Intravitreal Injections of Dexamethasone and Anti-Vascular Endothelial Growth Factor

Medicine and Dentistry

• Vasculotropin 100%
• Hazard Ratio 100%
• Dexamethasone 100%
• Intravitreal Administration 100%
• Drug Therapy 50%
• Incidence 33%
• Adverse Event 33%
• Eye Disease 33%
• Biological Marker 16%
• Follow up 16%
• Drug 16%
• Chemotherapeutic Agent 16%
• Combination Therapy 16%
• Patient 16%
• Glomerular Filtration Rate 16%
• Prevalence 16%
• Cataract Surgery 16%
• Medical Record 16%
• Retrospective Cohort Study 16%
• Diastolic Blood Pressure 16%
• Systolic Blood Pressure 16%
• Cause of Death 16%
• Alanine Aminotransferase 16%
• Heart Failure 16%
• Propensity Score Matching 16%
• Disease Management 16%
• Glycated Hemoglobin 16%
• Low-Density Lipoprotein 16%
• Major Bleeding 16%
• Major Adverse Cardiac Event 16%
• Glaucoma Surgery 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Vasculotropin 100%
• Dexamethasone 100%
• Adverse Event 33%
• Incidence 33%
• Eye Disease 33%
• Drug 16%
• Biological Marker 16%
• Prevalence 16%
• Cause of Death 16%
• Glaucoma 16%
• Heart Failure 16%
• Cohort Study 16%
• Alanine Aminotransferase 16%
• Low Density Lipoprotein 16%
• Cataract 16%
• Glycosylated Hemoglobin 16%
• Major Adverse Cardiac Event 16%
• Carbetimer 16%

Immunology and Microbiology

• Dexamethasone 100%
• Vasculotropin 100%
• Incidence 33%
• Prevalence 16%
• Density 16%
• Data Base 16%
• Systolic Blood Pressure 16%
• Medical Record 16%
• Heart 16%
• Diastolic Blood Pressure 16%
• Glomerulus Filtration 16%